- Home
- products
- north america
- drug design with structure based drug design
Show results for
Refine by
Applications
- Microbiome Therapeutics for Patients and Physicians
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Freeze-Dried Hemostatic for Patients
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- RNA Technology for Research Fellowship
- RNA Technology for Medical Areas of Focus Research
- RNA Technology for Product Pipeline Research
- RNA Technology for Clinical trials
Drug Design With Structure Based Drug Design Equipment Supplied In North America
53 equipment items found
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). This is a disease with significant commercial opportunity as ...
Manufactured by:Notitia Biotechnologies based inMonmouth Junction, NEW JERSEY (USA)
NM108 is an investigational botanical drug that is designed to treat diseases by promoting the growth of either the existing or replenished Foundation Guild™ bacteria in a patient's gut microbiome. NM108 is currently in phase 2 trial as well as available for Expanded Access (compassionate ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
MolEQ designs novel compounds by optimizing multiple properties such as efficacy and toxicity of a lead ...
by:Palvella Therapeutics. based inWayne, PENNSYLVANIA (USA)
QTORINTM rapamycin 3.9% is a novel topical therapy being studied for Pachyonychia Congenita (PC). We are currently enrolling our phase 3 study in ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-2900, Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage as a candidate for the treatment of Prader-Willi syndrome (PWS) and non-organic failure to thrive disease. TNX-2900 has been granted Orphan Drug Designation (ODD) in the US by the FDA for the treatment of ...
Manufactured by:Yukon Medical, LLC based inDurham,, NORTH CAROLINA (USA)
The Arisure Dry Spike gives you an easy, safe way to transfer fluid into a bag or container while maintaining a closed ...
Manufactured by:Kala Pharmaceuticals, Inc. based inArlington, MASSACHUSETTS (USA)
AMPPLIFY Drug Delivery Technology is designed to enhance penetration through the mucus barrier and deliver increased concentration of drug to the target ocular tissue. AMPPLIFY Drug Delivery Technology has been shown to improve delivery of loteprednol etabonate compared to traditional suspension eyedrops without ...
Manufactured by:RedHill Biopharma Ltd. based inTel-Aviv, ISRAEL
RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC). ...
Manufactured by:Notitia Biotechnologies based inMonmouth Junction, NEW JERSEY (USA)
BM306 is an investigational live biotherapeutic product that contains the Foundation Guild™ bacteria in a defined consortium. This investigational drug is designed to treat diseases by replenishing the missing or extinct Foundation Guild™ bacteria in a patient's gut ...
Manufactured by:Advin Biotech, Inc. based in, CALIFORNIA (USA)
Our new iSplit Cup and POCiT cup are examples of Advin’s focus on innovative engineering that result in improvements in the drug testing field. These designs remove steps in the lab and/or reduce shipping costs and storage footprint without the need for handling sharps or extra components. Both cups have patents pending and are exclusively available from Advin ...
Manufactured by:Alfa Scientific Designs, Inc based inPoway, CALIFORNIA (USA)
ALFA’s reliability for speed and accuracy in point of care rapid tests is readily available in the configuration you need. Our Multi-Drug Urine Cassette Test formats vary to our customers’ ...
Manufactured by:Shamrock Labels based inBellwood, ILLINOIS (USA)
The Shamrock Model SA-1 Anesthesia Drug Labels for Syringe Identification are designed for precise and clear labeling in critical medical environments. Each roll measures 1/2" x 500", providing ample length for extensive use. The labels come in a roll format with a removable adhesive, ensuring they can be easily applied and repositioned without leaving residue. Each roll contains 500 labels, ...
Manufactured by:Alfa Chemistry based inNY, NEW YORK (USA)
Introducing fluorine atom(s) into bioactive organic compounds has become a leading strategy for drug design and lead optimization. In drug synthesis strategy, fluorine is frequently employed to modify biologically relevant properties such as metabolic stability, basicity, lipophilicity and bioavailability. Additionally, the binding affinity of compounds to biological targets may also improve upon ...
Manufactured by:ApiJect Systems, Corp. based inStamford, CONNECTICUT (USA)
The ApiJect Platform brings together prefilled, single-dose parenterals with scalable, efficient manufacturing to solve drug delivery challenges for sterile liquid pharmaceuticals in all markets. ...
Manufactured by:Capricor Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), ...
by:Dominion Diagnostics based inNorth Kingstown, RHODE ISLAND (USA)
Having the most accurate tools available gives you confidence in decision-making and improves the quality of your care. Dominion Diagnostics offers valuable information to support screening, assessment and treatment planning for patients in addiction treatment programs. ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other ...
by:Curemark based inRye Brook, NEW YORK (USA)
The U.S. Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent ...